Company profile: Embecta
1.1 - Company Overview
Company description
- Provider of diabetes healthcare products and services, offering insulin syringes in various sizes, including 6mm needles and BD Veo with BD Ultra-Fine markings; BD AutoShield Duo pen needles with dual-end shields; accessories to support injections; and embassador Companion 24/7, a digital platform with educational content, health management tools, and diabetes-friendly recipes.
Products and services
- Insulin Syringes: Insulin-specific syringes engineered with various needle lengths and barrel sizes to enable accurate insulin delivery and accommodate different dosing requirements and user preferences
- BD AutoShield Duo™ pen needle: Safety-engineered pen needle with shields on both ends to minimize needlestick injuries and usable without pinch-up for straightforward insulin administration
- Embassador™ Companion 24/7: Digital platform delivering educational content, health management tools, and diabetes-friendly recipes to support daily self-care and informed decision-making for people with diabetes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Embecta
GI Dynamics
HQ: United States
Website
- Description: Provider of endoscopically delivered medical devices for managing type 2 diabetes, obesity, and related metabolic diseases, including RESET, which creates a barrier in the small intestine to improve insulin resistance and glycemic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GI Dynamics company profile →
Modulim
HQ: United States
Website
- Description: Provider of light-based imaging and care management solutions: Clarifi Imaging System, a non-contact, noninvasive tool using spatial frequency domain imaging to assess microvascular health by measuring tissue oxygenation and perfusion; LAMP, integrating patient assessment, data management, and care coordination; Modulim Cloud, a HIPAA-compliant platform for secure data and imaging; and Magnifi Software for tailored views and remote care collaboration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modulim company profile →
Jana Care
HQ: United States
Website
- Description: Provider of smartphone-based diagnostics and connected blood testing, using the Aina optical reader to turn smartphones into diagnostic platforms that analyze paper-based test strips across multiple assays; transmits results to physicians to enable telehealth and chronic disease monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jana Care company profile →
Serodus
HQ: Norway
Website
- Description: Provider of Scandinavian drug development focused on unmet needs in diabetes and diabetic comorbidities. In-licenses early-stage candidates and partners after Phase II proof of clinical effect. Pipeline includes SER150, an anti-inflammatory targeting diabetic kidney disease via thromboxane synthase inhibition and receptor blockade, and SER140, an IL-1β receptor antagonist for diabetic kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Serodus company profile →
Rubin Medical
HQ: Sweden
Website
- Description: Provider of diabetes aids for the public and healthcare sectors as a pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rubin Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Embecta
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Embecta
2.2 - Growth funds investing in similar companies to Embecta
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Embecta
4.2 - Public trading comparable groups for Embecta
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →